T2 Biosystems Stock Performance
| TTOO Stock | USD 0.01 0.01 50.00% |
T2 Biosystems holds a performance score of 12 on a scale of zero to a hundred. The firm owns a Beta (Systematic Risk) of -21.63, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning T2 Biosystems are expected to decrease by larger amounts. On the other hand, during market turmoil, T2 Biosystems is expected to outperform it. Use T2 Biosystems standard deviation and the relationship between the value at risk and market facilitation index , to analyze future returns on T2 Biosystems.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in T2 Biosystems are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of very fragile basic indicators, T2 Biosystems displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
TTOO |
T2 Biosystems Relative Risk vs. Return Landscape
If you would invest 1.20 in T2 Biosystems on October 8, 2025 and sell it today you would lose (0.70) from holding T2 Biosystems or give up 58.33% of portfolio value over 90 days. T2 Biosystems is currently generating 21.8854% in daily expected returns and assumes 140.8132% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than TTOO, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
T2 Biosystems Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for T2 Biosystems' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as T2 Biosystems, and traders can use it to determine the average amount a T2 Biosystems' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1554
| Best Portfolio | Best Equity | TTOO | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average T2 Biosystems is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of T2 Biosystems by adding it to a well-diversified portfolio.
T2 Biosystems Fundamentals Growth
TTOO Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of T2 Biosystems, and T2 Biosystems fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on TTOO Pink Sheet performance.
| Return On Equity | -6.22 | |||
| Return On Asset | -0.9 | |||
| Operating Margin | (4.91) % | |||
| Current Valuation | 21.91 M | |||
| Shares Outstanding | 21.04 M | |||
| Price To Earning | (2.04) X | |||
| Price To Book | 14.50 X | |||
| Price To Sales | 0.69 X | |||
| Revenue | 7.19 M | |||
| EBITDA | (43.88 M) | |||
| Cash And Equivalents | 13.21 M | |||
| Cash Per Share | 1.87 X | |||
| Total Debt | 49.5 M | |||
| Debt To Equity | 6.64 % | |||
| Book Value Per Share | (6.91) X | |||
| Cash Flow From Operations | (48.14 M) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 34.8 M | |||
| Retained Earnings | (584.3 M) | |||
| Current Asset | 77.78 M | |||
| Current Liabilities | 18.54 M | |||
About T2 Biosystems Performance
By examining T2 Biosystems' fundamental ratios, stakeholders can obtain critical insights into T2 Biosystems' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that T2 Biosystems is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts. T2 Biosystems operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 182 people.Things to note about T2 Biosystems performance evaluation
Checking the ongoing alerts about T2 Biosystems for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for T2 Biosystems help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| T2 Biosystems is way too risky over 90 days horizon | |
| T2 Biosystems has some characteristics of a very speculative penny stock | |
| T2 Biosystems appears to be risky and price may revert if volatility continues | |
| T2 Biosystems has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 7.19 M. Net Loss for the year was (50.08 M) with loss before overhead, payroll, taxes, and interest of (24.77 M). | |
| T2 Biosystems currently holds about 13.21 M in cash with (48.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 74.0% of the company shares are owned by institutional investors |
- Analyzing T2 Biosystems' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether T2 Biosystems' stock is overvalued or undervalued compared to its peers.
- Examining T2 Biosystems' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating T2 Biosystems' management team can have a significant impact on its success or failure. Reviewing the track record and experience of T2 Biosystems' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of T2 Biosystems' pink sheet. These opinions can provide insight into T2 Biosystems' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in TTOO Pink Sheet
T2 Biosystems financial ratios help investors to determine whether TTOO Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in TTOO with respect to the benefits of owning T2 Biosystems security.